TY - JOUR
T1 - The effect of neomycin on plasma alpha tocopherol levels in type II hyperlipoproteinemia
AU - Ayres, E. J.
AU - Hoeg, J. M.
AU - Bailey, K. R.
AU - Bieri, J. G.
PY - 1986
Y1 - 1986
N2 - Use of oral neomycin as a hypocholesterolemic agent was found to decrease plasma alpha tocopherol levels during a 9-month, randomized, crossover placebo-controlled clinical trial with controlled diet. Pooled data from each treatment sequence showed a placebo α-tocopherol level of 1,896 ± 643 μg/dl, and a neomycin α-tocopherol concentration of 1,449 ± 451 μg/dl (p < .01). When all subjects were on neomycin simultaneously, the level increased to 1,665 ± 614 μg/dl (p < .05 from placebo). Normal plasma α-tocopherol ranges from 400-1,000 μg/dl. Neomycin treatment reduces but does not normalize elevated levels of α-tocopherol found in Type II hyperlipoproteinemia.
AB - Use of oral neomycin as a hypocholesterolemic agent was found to decrease plasma alpha tocopherol levels during a 9-month, randomized, crossover placebo-controlled clinical trial with controlled diet. Pooled data from each treatment sequence showed a placebo α-tocopherol level of 1,896 ± 643 μg/dl, and a neomycin α-tocopherol concentration of 1,449 ± 451 μg/dl (p < .01). When all subjects were on neomycin simultaneously, the level increased to 1,665 ± 614 μg/dl (p < .05 from placebo). Normal plasma α-tocopherol ranges from 400-1,000 μg/dl. Neomycin treatment reduces but does not normalize elevated levels of α-tocopherol found in Type II hyperlipoproteinemia.
UR - http://www.scopus.com/inward/record.url?scp=0023032460&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023032460&partnerID=8YFLogxK
M3 - Article
C2 - 3792214
AN - SCOPUS:0023032460
SN - 0272-3530
VL - 4
SP - 325
EP - 331
JO - Drug-Nutrient Interactions
JF - Drug-Nutrient Interactions
IS - 4
ER -